Skip to content

A multicenter, prospective study of traditional Chinese medicine in the treatment of chronic atrophic gastritis based on the real world

A multicenter, prospective study of traditional Chinese medicine in the treatment of chronic atrophic gastritis based on the real world

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039873
Enrollment
Unknown
Registered
2020-11-13
Start date
2020-11-15
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic atrophic gastritis

Interventions

Sponsors

Affiliated Hospital of Shaanxi University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) The outpatients and inpatients with atrophic gastritis, mild, moderate and severe intestinal metaplasia or mild to moderate dysplasia were diagnosed by gastroscopy and histopathology; (2) Those who meet the diagnostic criteria of TCM syndromes; (3) The age ranged from 18 to 70 years old; (4) The subjects were informed and voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Severe dysplasia was diagnosed by histopathology; (2) Patients with history of peptic ulcer, gastric polyp and gastric surgery; (3) Long term use of NSAID drugs; (4) Patients suspected of gastric cancer or other systemic malignant lesions; (5) Patients with heart, cerebrovascular, liver, kidney, hematopoietic system and other primary diseases (ALT > 80 U / L, and / or ast > 80 U / L, renal dysfunction); (6) Mental illness, mental retardation and language disorder; (7) Patients with history of epilepsy and other central neuropathy; (8) Pregnant or preparing for pregnancy and lactation; (9) Allergic constitution and allergic history to the test drug or control drug.

Design outcomes

Primary

MeasureTime frame
Histopathological score of gastric mucosa;Pepsinogen determination;Determination of gastrin;Incidence of gastric cancer;

Secondary

MeasureTime frame
Symptom scores;Endoscopic mucosal lesion score;Based on the score of the patient reported clinical outcome scale (pro scale);

Countries

China

Contacts

Public ContactLiu Li

Shaanxi University of Traditional Chinese Medicine,

liuyan791@163.com+86 13909102189

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026